About Boston Biomedical
Boston Biomedical is a company based in Boston (United States) founded in 2006 was acquired by Sumitomo Dainippon Pharma in February 2012. Boston Biomedical has raised $2 million across 2 funding rounds from investors including HHS and Sumitomo Dainippon Pharma. Boston Biomedical operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
- Headquarter Boston, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$2 M (USD)
in 2 rounds
-
Latest Funding Round
$2 M (USD), Seed
Jun 15, 2010
-
Investors
HHS
& 1 more
-
Employee Count
Not available
-
Acquired by
Sumitomo Dainippon Pharma
(Feb 29, 2012)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Boston Biomedical
Boston Biomedical has successfully raised a total of $2M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $2 million completed in June 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Boston Biomedical
Boston Biomedical has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include HHS and Sumitomo Dainippon Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked | |
|
Pharmaceuticals, food ingredients, additives, and veterinary products are manufactured.
|
Locked | Locked | Locked |
Investor details for Boston Biomedical
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Boston Biomedical
Investment portfolio details for Boston Biomedical
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Boston Biomedical
Detailed financials for Boston Biomedical
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Boston Biomedical Comparisons
Peer comparison for Boston Biomedical
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Boston Biomedical
Boston Biomedical operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
Detailed competitors of Boston Biomedical
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Boston Biomedical
Complete news archive for Boston Biomedical
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Boston Biomedical
Boston Biomedical was founded in 2006 and raised its 1st funding round 4 years after it was founded.
Boston Biomedical is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Boston Biomedical is a funded company, having raised a total of $2M across 2 funding rounds to date.
Boston Biomedical is a privately held biotechnology company focusing on research and development of novel therapeutics to treat cancer. Beginning with initial focus on cancer stemcell pathways, company today has more than 20 clinical programs in pipeline. Two lead products at various phases of clinical trials for different types of cancer are Napabucasin and BB503. Other oncology programs include DSP-7888, an investigational agent approved by USFDA. Company got acquired by ds-pharma in 2012 for 200M USD upfront with milestone achievement being upto as high as 2.6B USD.
Boston Biomedical's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Boston Biomedical has 2 investors. Key investors include HHS, and Sumitomo Dainippon Pharma.